

Alice P Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3078412/publications.pdf>

Version: 2024-02-01

248
papers

12,095
citations

36303

51
h-index

30087

103
g-index

251
all docs

251
docs citations

251
times ranked

17890
citing authors

#	ARTICLE	IF	CITATIONS
1	Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using ⁶⁸ Ga-DOTATATE, FDG, ¹⁸ F-FDOPA, and Tl-201) <i>J Clin Oncol</i> , 2022, 40, 1552-1561.	10.7843	142
2	A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 49-58.	2.3	2
3	Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas. <i>Clinical Cancer Research</i> , 2022, 28, 279-288.	7.0	10
4	Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. <i>Journal of Clinical Oncology</i> , 2022, 40, 1552-1561.	1.6	26
5	Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. <i>JCO Precision Oncology</i> , 2022, 6, e2100424.	3.0	9
6	PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 165-180.	2.0	15
7	A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 721-735.	2.3	5
8	Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. <i>Cancer Cell</i> , 2021, 39, 38-53.e7.	16.8	65
9	The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1935-1939.	3.3	8
10	Effect of Capiwasertib in Patients With an AKT1 E17K-Mutated Tumor. <i>JAMA Oncology</i> , 2021, 7, 271.	7.1	49
11	Phase 1 study of Z-Endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors. <i>Oncotarget</i> , 2021, 12, 268-277.	1.8	6
12	Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2996-3004.	7.0	23
13	Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 749-760.	4.1	3
14	High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2021, 27, 2989-2995.	7.0	42
15	Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3834-3844.	7.0	36
16	A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3087-3087.	1.6	4
17	Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. <i>Gynecologic Oncology</i> , 2021, 161, 512-515.	1.4	4
18	Phase I trial of 5-aza-2'-deoxythio-2'-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3088-3088.	1.6	3

#	ARTICLE	IF	CITATIONS
19	Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).. Journal of Clinical Oncology, 2021, 39, 11519-11519.	1.6	36
20	Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors. Investigational New Drugs, 2021, 39, 1577-1586.	2.6	3
21	Abstract 3010: Single agent response comparisons in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute's patient-derived models repository. , 2021, , .		0
22	Abstract CT115: Phase I trial of the triplet berzosertib (M6620, VX-970), veliparib and cisplatin (BVP) in patients with advanced solid tumors. , 2021, , .		0
23	Abstract CT138: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes. Cancer Research, 2021, 81, CT138-CT138.	0.9	2
24	Abstract 3012: Patient-derived models of rare cancers in the National Cancer Institute's patient-derived models repository. , 2021, , .		0
25	Advances in the management of alveolar soft part sarcoma. Current Problems in Cancer, 2021, 45, 100775.	2.0	14
26	Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute. Oncologist, 2021, 26, e1883-e1886.	3.7	19
27	BRCA Mutation and PARP Inhibitors. , 2021, , 533-575.		1
28	Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. JCO Precision Oncology, 2021, 5, 133-144.	3.0	22
29	Abstract LBA003: Erdafitinib in patients with tumors harboring FGFR gene mutations or fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K2. , 2021, , .		2
30	Abstract P222: Combinations of receptor tyrosine kinase inhibitors targeting the tumor and stromal cells of complex spheroids from the National Cancer Institute's Patient-Derived Models Repository (PDMR; https://pdmr.cancer.gov/). , 2021, , .		0
31	Abstract P049: Phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with advanced non-small cell lung cancer. , 2021, , .		1
32	Clinical Evolution of Epithelial to Mesenchymal Transition in Human Carcinomas. Cancer Research, 2020, 80, 304-318.	0.9	71
33	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. Journal of the National Cancer Institute, 2020, 112, 1021-1029.	6.3	138
34	A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecologic Oncology, 2020, 156, 13-22.	1.4	9
35	Nivolumab Is Effective in Mismatch Repair Deficient Noncolorectal Cancers: Results From Arm Z1D A Subprotocol of the NCI-MATCH (EAY131) Study. Journal of Clinical Oncology, 2020, 38, 214-222.	1.6	106
36	Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial. JCO Precision Oncology, 2020, 4, 1207-1216.	3.0	6

#	ARTICLE	IF	CITATIONS
37	Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). <i>Journal of Clinical Oncology</i> , 2020, 38, 3883-3894.	1.6	168
38	Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> ^{V600E} Mutations: Results of the NCI-MATCH Trial Subprotocol H. <i>Journal of Clinical Oncology</i> , 2020, 38, 3895-3904.	1.6	145
39	The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa095.	0.7	15
40	Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 815-827.	2.3	12
41	553P Activity of trastuzumab and pertuzumab (HP) in patients with non-breast/gastroesophageal HER2-amplified tumours: Results of the NCI-MATCH trial (EAY131) subprotocol J. <i>Annals of Oncology</i> , 2020, 31, S479-S480.	1.2	3
42	Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study. <i>Oncologist</i> , 2020, 25, e1158-e1169.	3.7	11
43	Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. <i>Journal of Clinical Oncology</i> , 2020, 38, 2407-2417.	1.6	102
44	Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023). <i>Sarcoma</i> , 2020, 2020, 1-8.	1.3	33
45	Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline <i>BRCA</i> / <i>PALB2</i> Mutation. <i>Journal of Clinical Oncology</i> , 2020, 38, 1378-1388.	1.6	265
46	Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring <i>BRAF</i> Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). <i>Clinical Cancer Research</i> , 2020, 26, 1812-1819.	7.0	47
47	Intravenous 5-fluoro-2-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 979-993.	2.3	13
48	Phase II study of copanlisib in patients with tumors with <i>PIK3CA</i> mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3506-3506.	1.6	9
49	Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3612-3612.	1.6	12
50	A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g) <i>BRCA</i> / <i>PALB2</i> mutation.. <i>Journal of Clinical Oncology</i> , 2020, 38, 639-639.	1.6	8
51	Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas. <i>Oncotarget</i> , 2020, 11, 3959-3971.	1.8	8
52	Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3624-3624.	1.6	1
53	Abstract CT061: Binimetinib in patients with tumors with <i>NRAS</i> mutations: NCI-MATCH ECOG-ACRIN Cancer Research Group subprotocol EAY131-Z1A. , 2020, , .		0
54	Abstract 5056: Quality control efforts in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute's patient-derived models repository (NCI PDMMR). , 2020, , .		1

#	ARTICLE	IF	CITATIONS
55	Abstract 805: Intra-tumoral pharmacodynamics of selumetinib in serial biopsies from patients with neurofibroma. , 2020, , .		0
56	Abstract 802: Implementation of optimized research biopsy analyses for clinical pharmacodynamic (PD) studies. , 2020, , .		0
57	PARP Inhibition to Enhance Response to Chemotherapy. , 2019, , 231-257.		1
58	A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. British Journal of Clinical Pharmacology, 2019, 85, 2499-2511.	2.4	14
59	Genomic profiling of three pathways through molecular profiling-based assignment of cancer therapy (NCI- MPACT). Annals of Oncology, 2019, 30, v164-v165.	1.2	2
60	Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer Chemotherapy and Pharmacology, 2019, 84, 1289-1301.	2.3	29
61	Cediranib phase II study in children with metastatic alveolar soft part sarcoma (ASPS). Pediatric Blood and Cancer, 2019, 66, e27987.	1.5	11
62	The use of research biopsies in oncology trials: challenges and controversies. Journal of Hospital Management and Health Policy, 2019, 3, 7-7.	0.4	5
63	Impact of NCI-MATCH: a Nationwide Oncology Precision Medicine Trial. Expert Review of Precision Medicine and Drug Development, 2019, 4, 251-258.	0.7	8
64	Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Annals of Oncology, 2019, 30, 1821-1830.	1.2	99
65	Improving attribution of adverse events in oncology clinical trials. Cancer Treatment Reviews, 2019, 76, 33-40.	7.7	19
66	Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma. Frontiers in Oncology, 2019, 9, 53.	2.8	39
67	RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis. Journal of Clinical Oncology, 2019, 37, 1102-1110.	1.6	53
68	Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers. Clinical Cancer Research, 2019, 25, 3084-3095.	7.0	16
69	National Cancer Institute Basket/Umbrella Clinical Trials. Cancer Journal (Sudbury, Mass), 2019, 25, 272-281.	2.0	21
70	New Treatment Options for Ovarian Cancer. , 2019, , 533-540.		0
71	Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. Cancer Chemotherapy and Pharmacology, 2019, 83, 319-328.	2.3	9
72	Abstract B105: Phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas. , 2019, , .		2

#	ARTICLE	IF	CITATIONS
73	Abstract PR07: Phase II Trial of the MEK 1/2 inhibitor selumetinib (AZD6344, ARRY-142886 hydrogen) Tj ETQq1 1 0.784314 rgBT /Ove 2019, , .		2
74	Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing <i>BRCA1</i> and <i>BRCA2</i> mutations. Cancer Research, 2019, 79, CT138-CT138.	0.9	10
75	Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations. , 2019, , .		8
76	Abstract LB-010: Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: Phase II trial of palbociclib forCCND1, 2 or 3amplified tumors. , 2019, , .		4
77	Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 2619-2619.	1.6	3
78	A multiplex immunofluorescence assay to assess immune checkpoint inhibitor-targeted CD8 activation and tumor colocalization in FFPE tissues.. Journal of Clinical Oncology, 2019, 37, 2629-2629.	1.6	6
79	Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H.. Journal of Clinical Oncology, 2019, 37, 3002-3002.	1.6	10
80	Design and development of the molecular analysis for Therapy Choice (NCI-MATCH) Designated Laboratory Network.. Journal of Clinical Oncology, 2019, 37, 3016-3016.	1.6	2
81	Development and analytical validation of a 523-gene clinical assay for cell-free DNA.. Journal of Clinical Oncology, 2019, 37, 3039-3039.	1.6	1
82	A phase I study of veliparib incorporated into front-line platinum based cheotherapy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial.. Journal of Clinical Oncology, 2019, 37, 5523-5523.	1.6	5
83	Role of HSP90 Inhibitors in the Treatment of Cancer. Heat Shock Proteins, 2019, , 125-143.	0.2	0
84	Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors.. Journal of Clinical Oncology, 2019, 37, 3067-3067.	1.6	8
85	Pregnancies in subjects on oncology clinical trials: Analysis from the Cancer Therapy Evaluation Program (CTEP) database.. Journal of Clinical Oncology, 2019, 37, e18239-e18239.	1.6	0
86	Abstract CT099: DNA damage response and therapeutic activity following once-daily administration of the Wee 1 inhibitor AZD1775 (adavosertib). Cancer Research, 2019, 79, CT099-CT099.	0.9	1
87	Abstract LB-293: A Phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed metastatic colorectal carcinoma. , 2019, , .		1
88	Abstract LB-015: Phase I trial of recombinant human interleukin 15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers. , 2019, , .		0
89	Abstract 4524: Comparison of PDX, PDC, and PDOrg models from the National Cancer Instituteâ€™s Patient-Derived Models Repository (PDMR). , 2019, , .		1
90	Abstract A071: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
91	Abstract A050: Validation of β -catenin as a tumor segmentation marker for delineating tumor from stromal tissues in quantitative multiplex immunofluorescence analysis of formalin-fixed, paraffin-embedded biopsy specimens. , 2019, , .		0
92	Abstract A089: Adolescent and young adult (AYA) cohort of the NCI MATCH clinical trial (EAY131). , 2019, , .		0
93	Abstract C008: Tolerability and antitumor activity of paclitaxel is improved by the addition of nilotinib in patients with refractory solid tumors. , 2019, , .		0
94	Abstract B018: Restoration of p16INK4A expression in circulating tumor cells in patients with advanced solid tumors treated with deoxycytidine analogs and associated dynamic EMT phenotypic changes. , 2019, , .		0
95	Abstract A079: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH): A successful precision medicine signal-seeking trial in patients (pts) with rare variants and refractory malignancies. , 2019, , .		1
96	Abstract CT099: DNA damage response and therapeutic activity following once-daily administration of the Wee 1 inhibitor AZD1775 (adavosertib). , 2019, , .		0
97	Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing <i>BRCA1</i> and <i>BRCA2</i> mutations. , 2019, , .		0
98	Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations. , 2019, , .		0
99	Abstract LB-010: Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: Phase II trial of palbociclib for <i>CCND1, 2 or 3</i> amplified tumors. , 2019, , .		0
100	Abstract LB-015: Phase I trial of recombinant human interleukin 15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers. , 2019, , .		0
101	Abstract LB-293: A Phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed metastatic colorectal carcinoma. , 2019, , .		0
102	Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline <i>BRCA</i> mutation carriers and wild-type <i>BRCA</i> pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2018, 124, 1374-1382.	4.1	91
103	Hidradenitis Suppurativa-Like Lesions Associated with Pharmacologic Inhibition of γ -Secretase. <i>Journal of Investigative Dermatology</i> , 2018, 138, 979-981.	0.7	14
104	First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile. <i>Investigational New Drugs</i> , 2018, 36, 230-239.	2.6	32
105	Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e135-e142.	2.4	17
106	Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2018, 89, 19-26.	2.8	125
107	A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 744-752.	7.0	43
108	What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials?. <i>Journal of Oncology Practice</i> , 2018, 14, e722-e728.	2.5	31

#	ARTICLE	IF	CITATIONS
109	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2386-2394.	1.6	276
110	NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. <i>Cancer</i> , 2018, 124, 4332-4341.	4.1	15
111	Incorporating Patient-Reported Outcomes Into Early-Phase Trials. , 2018, , 193-208.		3
112	A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas. <i>Oncologist</i> , 2018, 23, 1269-e125.	3.7	13
113	Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GE) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 100-100.	1.6	20
114	Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 101-101.	1.6	29
115	Abstract 986: The National Cancer Institute's patient-derived models repository (PDMR). , 2018, , .		1
116	A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. <i>Gynecologic Oncology</i> , 2017, 144, 486-490.	1.4	47
117	Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 132, 181-188.	2.9	16
118	PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. <i>Drugs</i> , 2017, 77, 113-130.	10.9	44
119	Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. <i>Current Problems in Cancer</i> , 2017, 41, 182-193.	2.0	75
120	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. <i>Lancet Oncology</i> , The, 2017, 18, e143-e152.	10.7	1,612
121	Adenosine Triphosphate Quantification Correlates Poorly with Microbial Contamination of Duodenoscopes. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 678-684.	1.8	23
122	Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i> or <i>BRCA2</i> -Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. <i>Clinical Cancer Research</i> , 2017, 23, 4066-4076.	7.0	87
123	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4119-4126.	7.0	17
124	Randomized Comparison of 3 High-Level Disinfection and Sterilization Procedures for Duodenoscopes. <i>Gastroenterology</i> , 2017, 153, 1018-1025.	1.3	80
125	Phase I study of veliparib in combination with gemcitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 631-643.	2.3	11
126	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 697-706.	7.0	56

#	ARTICLE	IF	CITATIONS
127	A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 899-907.	7.0	37
128	Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay. <i>PLoS ONE</i> , 2017, 12, e0171582.	2.5	72
129	Clinical Activity of the β -Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive) <i>TJ ETQq1 1 0.784314 rgBT /O</i>	1.6	145
130	Abstract 4678: Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations. , 2017, , .		1
131	A phase I trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2518-2518.	1.6	1
132	Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents (TCA): Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2534-2534.	1.6	7
133	Suitability factors of core needle biopsies for pharmacodynamic (PD) studies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2540-2540.	1.6	1
134	Phase I study of indenoisoquinolines LMP776 in adults with relapsed solid tumors and lymphomas.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2558-2558.	1.6	9
135	Phase 1 study of onalespib, HSP90 inhibitor, and AT7519M, CDK9 inhibitor, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2617-TPS2617.	1.6	1
136	A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. <i>Oncotarget</i> , 2017, 8, 32918-32929.	1.8	46
137	Phase I trial of the triplet veliparib + VX-970 + cisplatin in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2609-TPS2609.	1.6	0
138	Abstract 845: A clinically validated multiplex immunofluorescence assay for the quantitative assessment of changes in EMT phenotypes in FFPE tumor tissues in response to cancer therapeutics. , 2017, , .		0
139	Abstract 3827: NCI 8628 - A randomized phase II study of Ziv-aflibercept (Z) and high dose Interleukin-2 (IL-2) or IL-2 alone for inoperable stage III or IV melanoma. , 2017, , .		0
140	Abstract 3840: The National Cancer Instituteâ€™s patient-derived models repository (PDMR). , 2017, , .		1
141	RECIST 1.1â€™ Update and clarification: From the RECIST committee. <i>European Journal of Cancer</i> , 2016, 62, 132-137.	2.8	1,143
142	Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 73-81.	2.3	32
143	Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials. <i>Seminars in Oncology</i> , 2016, 43, 446-452.	2.2	8
144	Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells. <i>Seminars in Oncology</i> , 2016, 43, 464-475.	2.2	89

#	ARTICLE	IF	CITATIONS
145	The root causes of pharmacodynamic assay failure. <i>Seminars in Oncology</i> , 2016, 43, 484-491.	2.2	11
146	RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. <i>European Journal of Cancer</i> , 2016, 62, 138-145.	2.8	211
147	New treatment option for ovarian cancer: PARP inhibitors. <i>Gynecologic Oncology Research and Practice</i> , 2016, 3, 3.	3.6	50
148	Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 51-67.	2.8	42
149	Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. <i>Investigational New Drugs</i> , 2016, 34, 355-363.	2.6	58
150	Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv437.	6.3	20
151	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 3227-3237.	7.0	85
152	N of 2 Responders With LMNA-NTRK1. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	6.3	0
153	Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis. <i>Cancer Research</i> , 2016, 76, CT101-CT101.	0.9	14
154	Activity of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11028-11028.	1.6	3
155	Feasibility of molecular profiling based assignment of cancer treatment (MPACT): A randomized NCI precision medicine study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2539-2539.	1.6	7
156	A phase 1 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2556-2556.	1.6	2
157	A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2 nd or 3 rd -line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8512-8512.	1.6	14
158	Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2596-TPS2596.	1.6	1
159	NCI-MATCH (Molecular Analysis for Therapy Choice) – a national signal finding trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2606-TPS2606.	1.6	6
160	Role of adaptive randomization in developing novel therapies for patients with breast cancer. <i>Translational Cancer Research</i> , 2016, 5, S1119-S1122.	1.0	1
161	Final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2584-2584.	1.6	2
162	Pazopanib to suppress MET signaling in patients with refractory advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2553-2553.	1.6	2

#	ARTICLE	IF	CITATIONS
163	Abstract CT121: Demographics of clinical trial participants for new molecular entity (NME) oncology drugs and biologics approved by FDA CDER in 2015. , 2016, , .		0
164	GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials. <i>Cancer Informatics</i> , 2015, 14s2, CIN.S17282.	1.9	18
165	Delivering on the promise. <i>Current Opinion in Oncology</i> , 2015, 27, 475-481.	2.4	20
166	A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation â€” An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2015, 137, 386-391.	1.4	224
167	Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or <i>BRCA</i>-Mutant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1574-1582.	7.0	124
168	A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis. <i>Clinical Cancer Research</i> , 2015, 21, 68-76.	7.0	65
169	Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 3409-3415.	1.6	261
170	Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv003-djv003.	6.3	52
171	Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 921-930.	2.6	44
172	Abstract CT325: Combination of the PARP inhibitor veliparib (ABT888) with irinotecan in patients with triple negative breast cancer: Preliminary activity and signature of response. <i>Cancer Research</i> , 2015, 75, CT325-CT325.	0.9	6
173	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias. <i>Blood</i> , 2015, 126, 1361-1361.	1.4	2
174	A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 1015-1015.	1.6	38
175	Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with <i>BRCA1</i>- or <i>BRCA2</i>- (<i>BRCA</i>-)-associated metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 520-520.	1.6	9
176	A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5507-5507.	1.6	18
177	A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancers: Trial of Princess Margaret, Mayo, Chicago, and California consortia.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS5613-TPS5613.	1.6	4
178	Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 358-358.	1.6	2
179	Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 170-170.	1.6	13
180	An overview of the NCI precision medicine trials-NCI MATCH and MPACT. <i>Chinese Clinical Oncology</i> , 2015, 4, 31.	1.2	53

#	ARTICLE	IF	CITATIONS
181	Using gamma-H2AX and H2AX quantitative ELISA for monitoring DNA damage induced by chemotherapeutic agents and irradiation exposure.. Journal of Clinical Oncology, 2015, 33, 2559-2559.	1.6	1
182	Abstract CT316: A phase I trial of oral TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with relapsed solid tumors. , 2015, , .		0
183	Veliparib (ABT-888), Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma. Blood, 2015, 126, 2691-2691.	1.4	0
184	National Cancer Institute's Precision Medicine Initiatives for the New National Clinical Trials Network. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 71-76.	3.8	141
185	Poly (<scp>ADP</scp>) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Medicine, 2014, 3, 1579-1594.	2.8	74
186	Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Journal of the National Cancer Institute, 2014, 106, dju244-dju244.	6.3	689
187	Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Quality of Life Research, 2014, 23, 257-269.	3.1	117
188	Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1 α), in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 73, 343-348.	2.3	129
189	Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors. Investigational New Drugs, 2014, 32, 340-346.	2.6	24
190	A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report. Neuro-Oncology, 2014, 16, 1661-1668.	1.2	60
191	Abstract 4643: Phase I pharmacokinetics and pharmacodynamics of a novel indenoisoquinoline topoisomerase 1 (TOP1) inhibitor, LMP400, administered on a daily x 5 schedule. Cancer Research, 2014, 74, 4643-4643.	0.9	1
192	Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96.. Journal of Clinical Oncology, 2014, 32, 1021-1021.	1.6	14
193	Phase I trial of AZD1775 (MK1775), a wee1 kinase inhibitor, in patients with refractory solid tumors.. Journal of Clinical Oncology, 2014, 32, 2503-2503.	1.6	3
194	Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt).. Journal of Clinical Oncology, 2014, 32, 2570-2570.	1.6	49
195	A phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis.. Journal of Clinical Oncology, 2014, 32, 4139-4139.	1.6	3
196	NCI impact: National Cancer Institute molecular profiling-based assignment of cancer therapy.. Journal of Clinical Oncology, 2014, 32, TPS2642-TPS2642.	1.6	8
197	Outcome of BRCA 1/2-mutated (BRCA+) and triple-negative, BRCA wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V).. Journal of Clinical Oncology, 2014, 32, 135-135.	1.6	13
198	NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanoma. Efficacy and biomarker study.. Journal of Clinical Oncology, 2014, 32, TPS9120-TPS9120.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Abstract 4689: Pre-clinical investigation of the wee1 inhibitor MK-1775 using pharmacodynamic and mechanistic markers in diverse cancer models in vivo. , 2014, , .		0
200	Safety and Early Efficacy Analysis of a Novel Combination of the PARP Inhibitor Veliparib (ABT-888) Plus Bendamustine and Rituximab in Patients with Lymphoma. Blood, 2014, 124, 1739-1739.	1.4	0
201	Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Targeted Oncology, 2013, 8, 117-125.	3.6	10
202	Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas. Cancer Chemotherapy and Pharmacology, 2013, 72, 917-923.	2.3	12
203	Molecular Pathways: Targeting PARP in Cancer Treatment. Clinical Cancer Research, 2013, 19, 977-984.	7.0	76
204	Abstract LB-139: Phase I trial of veliparib or mitomycin (MMC) + veliparib in patients with sporadic solid tumors screened for somatic deficiency in the Fanconi Anemia (FA) pathway.. , 2013, , .		0
205	BRCA Mutation and PARP Inhibitors. , 2013, , 417-447.		0
206	A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research, 2012, 18, 5081-5089.	7.0	22
207	A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas. Clinical Cancer Research, 2012, 18, 1726-1734.	7.0	186
208	Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer. Clinical Cancer Research, 2012, 18, 6023-6031.	7.0	81
209	Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0. Journal of the American Academy of Dermatology, 2012, 67, 1025-1039.	1.2	244
210	Poly(Adenosine Diphosphate-ribose) Polymerase Inhibitors in Cancer Treatment. Hematology/Oncology Clinics of North America, 2012, 26, 649-670.	2.2	24
211	Phase I study of the PARP inhibitor ABT-888 (veliparib) and pegylated liposomal doxorubicin (PLD) in recurrent ovarian (ov) and breast (br) cancers. Gynecologic Oncology, 2012, 125, S22.	1.4	1
212	Advances in using PARP inhibitors to treat cancer. BMC Medicine, 2012, 10, 25.	5.5	120
213	Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 69, 431-438.	2.3	24
214	Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Investigational New Drugs, 2012, 30, 749-757.	2.6	72
215	A phase I study of veliparib (ABT-888) in combination with carboplatin and paclitaxel in advanced solid malignancies.. Journal of Clinical Oncology, 2012, 30, 3049-3049.	1.6	11
216	A phase I study of chronically dosed, single-agent veliparib (ABT-888) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinum-refractory ovarian cancer, or basal-like breast cancer (BRCA-wt).. Journal of Clinical Oncology, 2012, 30, 3054-3054.	1.6	17

#	ARTICLE	IF	CITATIONS
217	Randomized trial of oral cyclophosphamide (C) with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma.. Journal of Clinical Oncology, 2012, 30, 5020-5020.	1.6	8
218	Abstract 4682: Compensatory activation of alternative DNA repair pathways following exposure to the PARP Inhibitor ABT-888in vitroand in patients with solid malignancies. , 2012, , .		0
219	Abstract 5586: Phase I study of PARP inhibitor ABT-888 and carboplatin with novel imaging in metastatic breast cancer (MBC) (NCI-8609). , 2012, , .		0
220	The Importance of Clinical Grading of Heart Failure and Other Cardiac Toxicities During Chemotherapy: Updating the Common Terminology Criteria for Clinical Trial Reporting. Heart Failure Clinics, 2011, 7, 373-384.	2.1	16
221	Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. European Journal of Cancer, 2011, 47, 997-1005.	2.8	23
222	Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Investigational New Drugs, 2011, 29, 1432-1440.	2.6	49
223	PARP Inhibitor Treatment in Ovarian and Breast Cancer. Current Problems in Cancer, 2011, 35, 7-50.	2.0	132
224	Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin. Clinical Cancer Research, 2011, 17, 6574-6581.	7.0	77
225	Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle, 2011, 10, 4074-4082.	2.6	37
226	Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors. Clinical Cancer Research, 2011, 17, 3794-3802.	7.0	49
227	Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas. Cancer Research, 2011, 71, 5626-5634.	0.9	228
228	Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology, 2011, 29, 2689-2695.	1.6	204
229	Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept. Clinical Cancer Research, 2011, 17, 4872-4881.	7.0	59
230	PARP inhibitors: its role in treatment of cancer. Chinese Journal of Cancer, 2011, 30, 463-471.	4.9	110
231	Abstract 1301: Investigation of a potential pharmacokinetic interaction between ABT-888 and topotecan in a phase I trial. , 2011, , .		0
232	A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Supportive Care in Cancer, 2010, 18, 509-522.	2.2	142
233	A rapid and sensitive method for determination of veliparib (ABT-888), in human plasma, bone marrow cells and supernatant by using LC/MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2010, 52, 122-128.	2.8	9
234	Abstract 3718: A Phase II Study of Sorafenib plus Cetuximab in colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR) and mutatedK-ras. , 2010, , .		0

#	ARTICLE	IF	CITATIONS
235	Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined With Topotecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias. <i>Blood</i> , 2010, 116, 3276-3276.	1.4	0
236	Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. <i>Cancer Biology and Therapy</i> , 2009, 8, 2004-2009.	3.4	22
237	Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies. <i>Journal of Clinical Oncology</i> , 2009, 27, 2705-2711.	1.6	303
238	Designing Phase 0 Cancer Clinical Trials. <i>Clinical Cancer Research</i> , 2008, 14, 3675-3682.	7.0	95
239	Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies. <i>Clinical Cancer Research</i> , 2007, 13, 5411-5417.	7.0	122
240	Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2007, 7, 325-334.	3.4	83
241	Assessment of Phospholipid Malabsorption by Quantification of Fecal Phospholipid. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2004, 39, 85-91.	1.8	9
242	Increased plasma homocysteine and S-adenosylhomocysteine and decreased methionine is associated with altered phosphatidylcholine and phosphatidylethanolamine in cystic fibrosis. <i>Journal of Pediatrics</i> , 2003, 143, 351-356.	1.8	47
243	Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 117-125.	2.3	11
244	A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 215-222.	2.3	12
245	The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. <i>Cancer Immunology, Immunotherapy</i> , 2000, 49, 517-529.	4.2	73
246	Phase I and Pharmacologic Study of Irinotecan Administered as a 96-Hour Infusion Weekly to Adult Cancer Patients. <i>Journal of Clinical Oncology</i> , 2000, 18, 659-659.	1.6	52
247	Phase I clinical trial of continuous infusion cyclopentenyl cytosine. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 513-523.	2.3	44
248	Phase I clinical trial of continuous infusion cyclopentenyl cytosine. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 513-523.	2.3	2